- Home
- PZG vs NRBO Comparison
PZG vs NRBO Comparison
Compare PZG & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZG
- NRBO
- Stock Information
- Founded
- PZG 1992
- NRBO N/A
- Country
- PZG United States
- NRBO United States
- Employees
- PZG N/A
- NRBO N/A
- Industry
- PZG Metal Mining
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- PZG Basic Materials
- NRBO Health Care
- Exchange
- PZG Nasdaq
- NRBO Nasdaq
- Market Cap
- PZG 26.3M
- NRBO 27.9M
- IPO Year
- PZG 1999
- NRBO N/A
- Fundamental
- Price
- PZG $0.44
- NRBO $2.19
- Analyst Decision
- PZG
- NRBO Strong Buy
- Analyst Count
- PZG 0
- NRBO 1
- Target Price
- PZG N/A
- NRBO $10.00
- AVG Volume (30 Days)
- PZG 250.7K
- NRBO 35.2K
- Earning Date
- PZG 11-12-2024
- NRBO 11-07-2024
- Dividend Yield
- PZG N/A
- NRBO N/A
- EPS Growth
- PZG N/A
- NRBO N/A
- EPS
- PZG N/A
- NRBO N/A
- Revenue
- PZG N/A
- NRBO N/A
- Revenue This Year
- PZG N/A
- NRBO N/A
- Revenue Next Year
- PZG N/A
- NRBO N/A
- P/E Ratio
- PZG N/A
- NRBO N/A
- Revenue Growth
- PZG N/A
- NRBO N/A
- 52 Week Low
- PZG $0.30
- NRBO $2.08
- 52 Week High
- PZG $0.69
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- PZG 60.98
- NRBO 31.67
- Support Level
- PZG $0.34
- NRBO $2.37
- Resistance Level
- PZG $0.45
- NRBO $2.99
- Average True Range (ATR)
- PZG 0.03
- NRBO 0.31
- MACD
- PZG 0.01
- NRBO -0.03
- Stochastic Oscillator
- PZG 92.59
- NRBO 0.62
About PZG Paramount Gold Nevada Corp.
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, it is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. It enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Paramount tries to realize the value of its projects by selling its projects to producers; joint venturing its projects with other companies; or building and operating small mines on its own. Its projects include sleeper gold, grassy mountain gold, frost project; other non-material, and mineral resources.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.